---
title: "STEP Trial"
description: "The STEP trial programme studied semaglutide for obesity, showing significant weight loss with lifestyle support."
canonical: "https://www.kesho.health/glossary/step-trial"
markdown_url: "https://www.kesho.health/md/glossary/step-trial"
language: "en-IN"
---

# STEP Trial

**Canonical HTML:** https://www.kesho.health/glossary/step-trial  
**Markdown:** https://www.kesho.health/md/glossary/step-trial

## Definition

STEP (Semaglutide Treatment Effect in People with obesity) trials evaluated weekly semaglutide for chronic weight management.

## Extended

STEP trials demonstrated roughly 10–15% body weight loss over 68 weeks. Extension studies showed weight regain after discontinuation, informing maintenance planning for Indian patients. In India, these concepts appear in RSSDI and ICMR guidance for type 2 diabetes and obesity care—always confirm details with your prescribing physician.

## Learn more

[Full guide](https://www.kesho.health/blog/semaglutide-india-complete-guide) · [MD](https://www.kesho.health/md/blog/semaglutide-india-complete-guide)

## Related terms

- [semaglutide](https://www.kesho.health/glossary/semaglutide)
- [obesity](https://www.kesho.health/glossary/obesity)
- [weight-regain-after-glp-1](https://www.kesho.health/glossary/weight-regain-after-glp-1)